(Q46970305)

27 December 2017

title

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide? (English)

1 reference

27 December 2017

interstitial lung disease

main subject

1 reference

Brigitte Ranque

3

0 references

Loïc Guillevin

4

object named as

Loïc Guillevin

1 reference

27 December 2017

author name string

Alice Bérezné

1

1 reference

27 December 2017

Dominique Valeyre

2

1 reference

27 December 2017

Luc Mouthon

5

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

27 December 2017

Annals of the New York Academy of Sciences

published in

1 reference

27 December 2017

volume

1110

1 reference

27 December 2017

page(s)

271-284

1 reference

27 December 2017

Scleroderma. Clinical problems. The lungs

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Differential diagnosis of periampullary carcinomas at MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

New insights into the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

Severe restrictive lung disease in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1423.029

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1423.029

1 reference

27 December 2017

1 reference

27 December 2017